BNTX

BioNTech SE

90.95 USD
+0.01 (+0.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioNTech SE stock is down -3.77% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Feb 18:58 19 Dec, 2025 90.00 CALL 40 15
21 Feb 15:19 20 Sep, 2024 85.00 PUT 58 736
21 Feb 15:34 20 Sep, 2024 85.00 PUT 64 736
21 Feb 15:42 15 Mar, 2024 115.00 PUT 23 0
22 Feb 15:06 15 Mar, 2024 110.00 PUT 20 48
26 Feb 17:43 17 Jan, 2025 80.00 PUT 100 724
27 Feb 15:41 19 Dec, 2025 90.00 PUT 100 116
28 Feb 20:10 21 Jun, 2024 85.00 PUT 100 870
29 Feb 15:28 20 Sep, 2024 95.00 CALL 50 107
29 Feb 15:30 17 Jan, 2025 95.00 CALL 50 524

About BioNTech SE

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.

  • Canaccord Genuity
    Fri Feb 23, 10:11
    buy
    confirm
  • BMO Capital
    Fri Feb 23, 06:28
    buy
    initial
  • Canaccord Genuity
    Wed Feb 21, 09:19
    buy
    confirm
  • Canaccord Genuity
    Tue Feb 20, 09:56
    buy
    confirm